High Growth Tech Stocks In Hong Kong To Watch

Amidst a backdrop of mixed global market performances and economic indicators, the Hong Kong technology sector has shown resilience, with the Hang Seng Index gaining 2.14% recently. In this environment, identifying high-growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to shifting market dynamics.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	45.88%	45.90%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.23%	★★★★★★
Akeso	32.46%	55.03%	★★★★★★
Innovent Biologics	21.31%	59.83%	★★★★★☆
RemeGen	26.30%	52.19%	★★★★★☆
Sichuan Kelun-Biotech Biopharmaceutical	26.67%	9.08%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆

Click here to see the full list of 47 stocks from our SEHK High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

SUNeVision Holdings (SEHK:1686)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: SUNeVision Holdings Ltd., an investment holding company, provides data centre and information technology (IT) facility services in Hong Kong, with a market cap of HK$13.68 billion.

Operations: SUNeVision Holdings Ltd. generates revenue primarily through its data centre and IT facilities services, contributing HK$2.46 billion, and from extra-low voltage (ELV) and IT systems, which add HK$213.03 million.

SUNeVision Holdings Ltd. reported a 13.6% annual earnings growth forecast, outpacing the Hong Kong market's 10.9%. Revenue is expected to rise by 15.6% annually, significantly higher than the market average of 7.5%. For the fiscal year ending June 30, 2024, sales reached HKD2.67 billion compared to HKD2.35 billion last year, with net income at HKD907 million from HKD905 million previously. The company has also proposed a final dividend of HKD0.112 per share for this period.

• Delve into the full analysis health report here for a deeper understanding of SUNeVision Holdings.

• Review our historical performance report to gain insights into SUNeVision Holdings''s past performance.

Sunny Optical Technology (Group) (SEHK:2382)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Sunny Optical Technology (Group) Company Limited, an investment holding company, engages in designing, researching, developing, manufacturing, and selling optical and optical-related products as well as scientific instruments with a market cap of HK$52.76 billion.

Operations: Sunny Optical Technology (Group) generates revenue primarily from three segments: Optical Components (CN¥12.32 billion), Optoelectronic Products (CN¥25.10 billion), and Optical Instruments (CN¥0.59 billion). The company's diversified product portfolio includes optical and optoelectronic products, along with scientific instruments.

Sunny Optical Technology (Group) has seen remarkable growth, with earnings increasing by 17.2% over the past year and revenue expected to grow at an annual rate of 10.2%. For the first half of 2024, sales surged to CNY18.86 billion from CNY14.28 billion a year ago, while net income rose to CNY1.08 billion from CNY436.71 million previously. The company's R&D expenses reflect a strong commitment to innovation, contributing significantly to its competitive edge in the smartphone lens and camera module market.

• Dive into the specifics of Sunny Optical Technology (Group) here with our thorough health report.

• Evaluate Sunny Optical Technology (Group)'s historical performance by accessing our past performance report.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of HK$42.47 billion.

Operations: Akeso, Inc. generates revenue primarily through the research, development, production, and sale of biopharmaceutical products, amounting to CN¥1874.14 million. The company focuses on antibody drugs within the biopharmaceutical sector.

Akeso's revenue dropped to ¥1.02 billion from ¥3.68 billion YoY, with a net loss of ¥238.59 million compared to a previous net income of ¥2.53 billion. Despite this, Akeso's R&D expenses underscore its commitment to innovation, particularly in the biotech sector where it invests heavily in developing groundbreaking therapies like ivonescimab and AK117 for cancer treatment. With revenue growth projected at 32.5% annually and earnings expected to rise by 55%, Akeso shows potential for significant future advancements in oncology treatments through its robust pipeline and strategic focus on high-impact drug development initiatives.

• Click here to discover the nuances of Akeso with our detailed analytical health report.

• Learn about Akeso's historical performance.

Taking Advantage

• Access the full spectrum of 47 SEHK High Growth Tech and AI Stocks by clicking on this link.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com